ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tamsulosin

Also written as “tamsulosin hydrochloride”, “Tamsulosin (0.4 mg/j)” and “tamsulosin”.

Its studies are mostly in Prostatic Hyperplasia · Lower Urinary Tract Symptoms · Erectile Dysfunction · Urologic Diseases · Urinary Bladder, Neurogenic, led by 15 companies.

Drug pageTamsulosin: every studyMany companies study it; this page follows only the 56 they lead. All 155 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 18, 201456 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim140 open or runningphase 4since Sep 18, 2014Jun 19, 2006none ahead
Astellas Pharmaits history only100 open or runningphase 4since Mar 17, 2016Jul 25, 2007none ahead
GlaxoSmithKlineits history only90 open or runningphase 4since Feb 10, 2011Aug 24, 2004none ahead
Hanmi Pharmaceuticalits history only50 open or runningphase 3since Feb 23, 2015Sep 4, 2014none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Sep 2, 2015Sep 15, 2014none ahead
Menarini Groupits history only33 open or runningphase 1since Jul 22, 2025Jul 22, 2025none ahead
GL Pharm Techits history only20 open or runningphase 3since Nov 11, 2014Feb 24, 2014none ahead
Jeil Pharmaceuticalits history only20 open or runningphase 3since Nov 21, 2016Jul 1, 2014none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Jun 22, 2010Jun 22, 2010none ahead
ADIUMits history only10 open or runningno phasesince Jul 7, 2026Jul 7, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 19, 2006First study: phase 2 study in Urinary Bladder, NeurogenicFirst studyNCT00340704 · 143 enrolled · United States, Belgium, Brazil and more
  2. Nov 20, 2008Phase 3 study in Urinary Bladder, NeurogenicNCT00796614 · 231 enrolled · United States, Belgium, Brazil and more
  3. Nov 9, 2012Phase 2 study in Lower Urinary Tract SymptomsNCT01726270 · 689 enrolled · United States
  4. Sep 18, 20142 phase 2 studiesNCT02244294, NCT02244281
  5. Sep 18, 20143 phase 4 studies in Prostatic HyperplasiaNCT02244255, NCT02244242, NCT02244229
  6. Oct 14, 20144 phase 1 studiesNCT02264184, NCT02266537, NCT02266524 and 1 more
  7. Apr 13, 2015Phase 1 study in Prostatic HyperplasiaNCT02417844 · 34 enrolled
  8. Oct 1, 2015Phase 3 study in Urological ManifestationsNCT02573311 · 1,117 enrolled · United States

TargetBeta

“Adrenergic receptor alpha-1 antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
MidodrineruleTakedaphase 410
PrazosinrulePfizerphase 34

Studies

All 14 Boehringer Ingelheim leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02573311Urological Manifestations · United States3CompletedAug 1, 20161,117
NCT02417844Prostatic Hyperplasia1CompletedMay 201534
NCT02266537Healthy1CompletedFeb 200697
NCT02266524Urination Disorders1CompletedApr 200548
NCT02266511Healthy1CompletedSep 199930
NCT02264184Healthy1CompletedDec 200824
NCT02244294Prostatic Hyperplasia2CompletedJun 2005176
NCT02244281Lower Urinary Tract Symptoms2CompletedNov 200374
NCT02244255Prostatic Hyperplasia4CompletedJun 20001,993
NCT02244242Prostatic Hyperplasia4CompletedAug 1999493
NCT02244229Prostatic Hyperplasia4CompletedNov 2000403
NCT01726270Lower Urinary Tract Symptoms · United States2CompletedMar 2013689
NCT00796614Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more3CompletedFeb 2009231
NCT00340704Urinary Bladder, Neurogenic · United States, Belgium, Brazil and more2CompletedJun 2009143

How it is read

Names in the registry

  • “Tamsulosin”, 12 entries
  • “tamsulosin hydrochloride”, 6 entries
  • “Tamsulosin (0.4 mg/j)”, 5 entries
  • “tamsulosin”, 4 entries
  • “HIP1402”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.